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Abstract 
The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) 
nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized 
trial comparing 2-Gy TBI alone, or in combination with 90 mg/m
2
 fludarabine (FLU/TBI), before 
transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five 
patients with hematological malignancies were randomized to be conditioned with TBI alone 
(n = 44) or FLU/TBI (n = 41). All patients had initial engraftment. Two graft rejections were 
observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease 
(GVHD) were similar between groups. Three-year overall survival was lower in the TBI group 
(54% versus 65%; hazard ratio [HR], .57; P = .09), with higher incidences of relapse/progression 
(55% versus 40%; HR, .55; P = .06), relapse-related mortality (37% versus 28%; HR, .53; P = .09), 
and a lower progression-free survival (36% versus 53%; HR, .56; P = .05). Median donor T cell 
chimerism levels were significantly lower in the TBI group at days 28 (61% versus 90%; P < .0001) 
and 84 (68% versus 92%; P < .0001), as was NK cell chimerism on day 28 (75% versus 96%; P = 
.0005). In conclusion, this randomized trial demonstrates the importance of fludarabine in 
augmenting the graft-versus-tumor effect by ensuring prompt and durable high-level donor 
engraftment early after transplantation. 
 
During the development of the widely used nonmyeloablative conditioning regimen based on 2-Gy 
low-dose total body irradiation (TBI) and 90 mg/m
2
 fludarabine (FLU), the first 44 patients in the 
initial clinical trial were conditioned with a regimen directly translated from our canine studies 1, 
2 and 3. The regimen consisted of 2-Gy TBI alone, and although results were encouraging, a 
nonfatal graft rejection rate of 20% was observed [4]. To reduce the high rejection rate, FLU 
(30 mg/m
2
/day for 3 days) was added to the 2-Gy TBI, which resulted in a decrease in rejections to 
3% [5]. However, in a retrospective analysis of the first 176 patients with hematologic malignancies 
treated with nonmyeloablative hematopoietic cell transplantation (HCT) from HLA-identical related 
donors, higher nonrelapse mortality (NRM) was observed among patients conditioned with 2-Gy 
TBI and FLU (FLU/TBI) (FLU/TBI: 31% versus TBI:14% at 2 years; P = .02). The increased NRM 
was due to increased infectious events with or without graft-versus-host disease (GVHD) [5]. 
As rejections were mainly observed in patients who had not been treated with significant 
myelosuppressive chemotherapy [5] (myeloid malignancies or multiple myeloma) before allogeneic 
HCT, we hypothesized that in patients at a low risk of rejection, conditioning with 2-Gy TBI alone 
could be sufficient to allow stable long-term engraftment. These results needed to be taken with 
caution, however, as they were retrospective and not from concurrent transplantation cohorts. 
Therefore, we initiated this phase III trial, where patients at low or moderate risk of rejection were 
randomized between conditioning with 2-Gy TBI alone or in combination with FLU (30 mg/m
2
/day 
for 3 days)/FLU/TBI) before transplantation with peripheral blood stem cells (PBSC) from human 
leukocyte antigen (HLA)-matched related donors. 
 
 
Patients and Methods 
The study was a randomized phase III trial including 9 transplantation centers: Fred Hutchinson 
Cancer Research Center (FHCRC), Medical College of Wisconsin, University of Leipzig, Oregon 
Health and Science University, VA Puget Sound Health Care System Huntsman Cancer 
Institute/University of Utah, University of Torino School of Medicine, LDS Hospital, University of 
Tuebingen, and University of Cologne. The FHCRC acted as the coordinating center. The study 
was approved by the institutional review board at each center, and written informed consent was 
obtained from all patients before the start of treatment. 
 
Randomization, Study Endpoints, and Accrual 
 
Patients were randomized equally between conditioning with 2-Gy TBI alone or in combination 
with FLU 30 mg/m
2
/day for 3 days. The randomization was performed at the FHCRC and was 
stratified balanced over time for institution, disease risk (indolent versus aggressive) [6], and a 
history of prior high-dose HCT. 
The initial primary endpoint was the comparison of 1-year NRM between arms. However, as 
accrual was slow, and it was unlikely that the enrollment goal of 200 patients would be met within a 
reasonable timeframe, the data safety monitoring board recommended a change of the primary 
objective to overall survival at 3 years to accommodate a lower accrual goal of 110 patients. Apart 
from including NRM at 1 year in the secondary objectives, the rest of the secondary objectives 
remained the same (disease progression, relapse-related mortality, graft rejection, grades II to IV 
acute and chronic GVHD, infections, and immune reconstitution). 
The protocol was opened for accrual in December 2003 and closed by the principal investigator 
(with data safety-monitoring board approval) in May 2011, after accruing 85 patients, because of a 
difference in relapse and progression rates between the 2 arms. 




Included in this study were patients with hematological malignancies treatable by allogeneic HCT 
who were not curable by high-dose conditioning with autologous stem cell support and ineligible 
for high-dose allogeneic HCT because of age or comorbidities. Donors were related and at least 
genotypically HLA identical at 1 haplotype and phenotypically or genotypically identical at the 
allele level at HLA-A, -B, -C, -DRB1 and -DQB1 for the second haplotype [7]. The hematological 
malignancies allowed were aggressive non-Hodgkin lymphomas (NHLs); low-grade NHL with 
<6 months' duration of complete remission (CR) between courses of therapy; mantle cell 
lymphoma; chronic lymphocytic leukemia (CLL) that did not meet the National Cancer Institute's 
Working Group criteria for CR, partial remission, or relapse within 12 months after FLU or other 
nucleoside analogue-containing therapy; failed FLU-cyclophosphamide-rituximab therapy, had 17p 
deletion; progressed to prolymphocytic leukemia or T cell CLL or prolymphocytic leukemia; 
Hodgkin lymphoma (HL) that had at least failed frontline therapy and were ineligible for or had 
failed high-dose conditioning with autologous stem cell support; multiple myeloma (MM) that was 
chemotherapy sensitive after failed high-dose conditioning with autologous stem cell support; acute 
myeloid leukemia (AML) or acute lymphoblastic leukemia beyond first CR; chronic myeloid 
leukemia (CML) beyond the first chronic phase after myelosuppressive therapy; myelodysplastic 
syndrome (MDS) or myeloproliferative disease after myelosuppressive therapy; or Waldenstrom's 
macroglobulinemia after failing 2 courses of therapy. Patients with CML, AML, acute 
lymphoblastic leukemia, MDS, or myeloproliferative disease required < 5% marrow blasts at the 
time of transplantation. Myelosuppressive therapy less than 3 weeks before conditioning or high-
dose conditioning with stem cell support less than 6 months before allogeneic HCT was not 
allowed. 
Patients were excluded from the trial if they were pregnant or breast-feeding; had rapidly 
progressing intermediate- or high-grade NHL, unless in minimal disease state; chronic 
myelomonocytic leukemia, leukemic blasts in the peripheral blood detected by standard pathology; 
central nervous system involvement refractory to intrathecal chemotherapy; infection with human 
immunodeficiency virus, bacterial, viral, or fungal infections unresponsive to therapy; 
decompensated liver disease; lung carbon monoxide diffusion capacity <30%, total lung capacity 
<30%, forced expiratory volume <30%, or dependency on supplementary oxygen; symptomatic 
coronary artery disease or cardiac ejection fraction <35%; poorly controlled hypertension; or a 
Karnofsky performance score <50%. 
 
Treatment and Evaluations 
 
Patients allocated to the TBI-only arm received 2 Gy at a rate of .07 Gy/min to .10 Gy/min from a 
linear accelerator on the day of HCT (day 0) with PBSC, whereas patients in the FLU/TBI arm in 
addition received FLU (30 mg/m
2
/day) on days -4, -3, and -2 before 2-Gy TBI and HCT. PBSC 
were collected from related donors on days -1 and 0 (CD34
+
 target cell dose was 5 × 10
6
 cells/kg of 
recipient weight) after administration of granulocyte colony-stimulating factor (G-CSF) (16 μg/kg) 
on days -4 to 0. Postgrafting immunosuppression consisted of oral cyclosporine (CSP; 5 mg/kg 
twice daily from days -3 to +56, and, in the absence of GVHD, tapered by 6% weekly until 
day +180) and mycophenolate mofetil (15 mg/kg twice daily from day 0 to +27). CSP levels were 
monitored by immunoassay, and whole blood trough levels were targeted at 500 ng/mL for the first 
28 days after transplantation and at 150 ng/mL to 450 ng/mL until the start of taper (Abbott, TDX, 
Abbott Park, IL). If there was evidence of persistent/progressive disease or relapse in the absence of 
GVHD on day 56 after transplantation, all immunosuppressive agents were rapidly tapered to allow 
graft-versus-tumor effects to occur. If relapse was observed, these cases were considered treatment 
failures, and the patients were taken off protocol. Donor lymphocyte infusion (DLI) was not offered 
on this protocol, and patients with low chimerism or disease progression were eligible for ongoing 
DLI protocols or treatment plans. For the purpose of survival analysis, patients were followed past 
the time point of relapse or DLI. Chimerism analysis was performed as previously described [8]. 
Peripheral blood CD3
+
 T cell chimerism studies were performed on days +28, +84 and +365, and, if 
the patient had <50% donor chimerism on day 28, additional analyses were performed on days +56 
and +180. If the patient was not >95% CD3
+
 T cell donor chimerism at 1 year, analyses were 
repeated annually. Natural killer (NK) cell (CD56) and granulocyte (CD33) chimerisms were 
obtained on days +28 and +84, respectively. Full-donor chimerism was defined as >95% donor 
CD3
+
 T cells, and graft rejection was defined as the inability to detect at least 5% donor CD3
+
 T 
cells in peripheral blood. Toxicities were determined using the Common Toxicity Criteria, Version 
2.0 [9]. 
All patients received standard prophylaxis against infections as previously published [10]. 
Diagnosis, clinical grading, and treatment of acute and chronic GVHD were performed by local 
investigators according to established criteria 11 and 12. Tumor responses were assessed using 
standard criteria and PCR, cytogenetics, fluorescein in situ hybridization, and flow cytometric-
based methods as appropriate. 
 
Analysis of Peripheral Blood Lymphocytes 
 
Immunnophenotyping of peripheral blood lymphocytes was only performed in a subset of 
patient/donor pairs that underwent transplantation at the FHCRC. Peripheral blood was obtained 
from donors pre-G-CSF and from patients before transplantation and at days +28, +84, +180 
and +365. Enumeration of mononuclear cell subsets [13] and immunophenotyping by flow 




 T cells, 
monocytes, NK cells, and myeloid and plasmacytoid dendritic cells were performed as previously 




Survival was estimated by the Kaplan-Meier method. Cumulative incidence was estimated by 
standard methods in the competing risk setting. Nonrelapse death was a competing risk for the 
analysis of relapse/progression and relapse-related mortality, and, conversely, relapse/progression 
was a competing risk for the analysis of nonrelapse death. Death was a competing risk for the 
analysis of acute and chronic GVHD and infection. All statistical comparisons of time-to-event 
endpoints are based on hazard ratio (HR) analysis using Cox regression. Comparisons of chimerism 
are based on 2-sample Wilcoxon test. Comparisons of immune reconstitution are based on 2-sample 





Forty-four patients were accrued into the TBI-only arm, and 41 were accrued into the FLU/TBI 
arm. Patient demographics are summarized in Table 1. Overall median patient age was 55 (range, 
17 to 73) years with a predominance of male gender (68%). Patients received G-CSF–mobilized 
PBSC containing a median of 7.9 × 10
6
 (range, 1.9 × 10
6




 cells/kg and 
3.6 × 10
8
 (range, 1.0 × 10
8




 cells/kg. Underlying diseases were AML (n = 15), 
MDS (n = 4), NHL (n = 32), CLL (n = 9), MM (n = 9), and HL (n = 16) with slightly more patients 
with NHL compared with AML and lower relapse risk score [15] in the FLU/TBI arm, but this was 
not statistically different and within the limits expected by chance. Fifty-five percent of the patients 
had failed at least 1 high-dose HCT. As randomization was stratified upon failed prior high-
dose HCT, the number of patients was evenly distributed between arms (TBI only, n = 26 [59%]; 
FLU/TBI, n = 21 [51%]). In the TBI arm, 3 of 26 patients had failed an allogeneic HCT (all from 
different HLA-matched siblings) compared with none in the FLU/TBI arm. There was no difference 
in median HCT comorbidity index between arms [16]. Four patients in the TBI arm and 3 in the 
FLU/TBI arm, all with refractory or relapsed CD20
+
 B cell lymphomas, were concurrently enrolled 
on a protocol (ClinicalTrials.gov identifier: NCT00867529) studying the effects of 
peritransplantation rituximab (days -3, 10, 24 and 38). 
 
Table 1.  
Pretransplantation Demographics 
Characteristic TBI Only (n = 44) Flu/TBI (n = 41) 
Patient age, median (range), yr 54 (17-73) 56 (18-72) 
Male patient gender 32 (73) 26 (63) 
Donor age, median (range), yr 53 (17-73) 54 (15-71) 
Sex of patient/donor   
 Male/female 15 (34) 15 (37) 
 Other combinations 29 (66) 26 (63) 
CMV serostatus of patient/donor   
 Negative/negative 14 (32) 12 (29) 
 Other combinations 30 (68) 29 (71) 
Prior failed high-dose HCT   
 Autologous 23 (52) 21 (51) 
Characteristic TBI Only (n = 44) Flu/TBI (n = 41) 
 Allogeneic 3 (7) 0 
Number of previous regimens, median (range) 5 (1-17) 5 (1-19) 
Diagnoses   
 Non-Hodgkin lymphoma 14 (32) 18 (44) 
 Acute myeloid leukemia 10 (23) 5 (12) 
 Multiple myeloma 5 (11) 4 (10) 
 Chronic lymphocytic leukemia 5 (11) 4 (10) 
 Myelodysplastic syndrome 2 (5) 2 (5) 
 Hodgkin lymphoma 8 (18) 8 (20) 
Relapse risk [15]   
 Low 9 (20) 14 (34) 
 Standard 18 (41) 12 (29) 
 High 17 (39) 15 (37) 
HCT comorbidity index   
 0 13 (30) 6 (15) 
 1,2 6 (14) 13 (33) 
 3+ 24 (56) 20 (51) 
CD34
+
 cells × 10
6
/kg, median (range) 7.9 (2.6-19.8) 7.7 (1.9-22.7) 
CD3 + cells × 10
8
/kg, median (range) 3.7 (1.4-40.9) 3.5 (1.0-9.7) 
Data presented as n (%) unless otherwise indicated. 
 
Peripheral Blood Cell Changes, Rejections, and Chimerism 
All patients had initial engraftment. Although no patients in the FLU/TBI arm rejected their grafts, 
2 patients in the TBI arm, 1 with AML in second CR and 1 with MDS (refractory anemia with 
excess of blasts-2), experienced graft rejection 31 and 262 days after transplantation, respectively. 
The patient with AML had failed a prior allogeneic high-dose HCT from a different HLA-matched 
sibling, and after rejecting the graft from the current 2-Gy TBI-conditioned HCT, went on to 
receive a third allogeneic HCT from the same sibling and subsequently died from disease 
progression. The patient with MDS was in complete remission before transplantation, having 
received only 1 cycle of cytarabine and mitoxantrone. After rejecting the graft on this trial, the 
patient received a second myeloablative transplantation from a syngeneic donor. The patient was 
still alive and in remission at last follow-up. 
Near-complete donor granulocyte chimerism was achieved promptly, with no significant 
differences between arms (Figure 1A). Median donor T cell chimerism levels were significantly 
higher in the FLU/TBI arm compared with the TBI arm at days +28 (90% versus 61%; P < .0001) 
and +84 (92% versus 68%; P < .0001) ( Figure 1B). Median day +28 NK cell donor chimerism was 
also significantly higher in FLU/TBI-conditioned patients (FLU/TBI [n = 14], 96%; TBI [n = 15], 
75%; P = .0005) and correlated with day +28 donor T cell chimerism (Pearson's correlation 
coefficient = .82; P < .0001). 
 
Figure 1.  
Donor granulocyte and T cell chimerism. Percent donor granulocyte (A) and T cell chimerism 
(B) in patients conditioned with 2-Gy total body irradiation only (TBI, n = 44) or in 
combination with 90 mg/m
2
 fludarabine (FLU/TBI, n = 41). Horizontal lines represent 
medians, and dots represent the individual data points. P values are 2 tailed. 
 
Median absolute granulocyte count nadirs were similar in the 2 groups (TBI: 396 [range, 0 to 2340] 
cells/μL; FLU/TBI: 270 [0 to 1090] cells/μL; P = .32). However, the median number of days with 
absolute granulocyte counts below 500 cells/μL was significantly higher in the FLU/TBI group 
(TBI: 0 [range, 0 to 40] days; FLU/TBI: 4 [range, 0 to 17] days; P = .05), but the number of patients 
who required G-CSF treatment for prolonged neutropenia (persistence or development of 
granulocyte counts below 500 cell/μL past day +21 after transplantation) was similar (TBI: 12%; 
FLU/TBI: 18%; P = .45). Platelet nadirs (TBI: 59,000 [range, 6000 to 251,000] platelets/μL; 
FLU/TBI: 59,000 [range, 6000 to 209,000] platelets/μL; P = .62) and days below platelet counts of 
20,000 platelets/μL (TBI: 0 [range, 0 to 24] days; FLU/TBI: 0 [range, 0 to 3] days; P = .63) were 
similar in both arms. The percentages of patients who needed red blood cell transfusions trended to 
be higher in the FLU/TBI arm (TBI: 43%; FLU/TBI: 63%; P = .06), whereas the percentages of 








None of the patients in the FLU/TBI arm received DLI. A total of 8 patients in the TBI arm 
received DLI: 2 patients because of low chimerism (both died from relapsed AML) and 6 patients 
because of relapse or progression (4 died from relapse, whereas 1 with HL and 1 with small 




In the TBI arm, samples for immunophenotyping were available from 16 patients at day 28 and 
from 8 patients at day 90, whereas in the FLU/TBI arm, samples were available from 7 and 13 
patients at days 28 and 90, respectively. 
Immunophenotyping showed that the median absolute number of NK cells was significantly higher 
at day +28 after transplantation in the FLU/TBI arm compared with the TBI arm (Figure 2). The 
difference disappeared by day +90. No differences between arms were observed for the median 
absolute number of CD4
+
 cells at day +28, but at day +90, lower levels were observed in patients in 
the FLU/TBI arm compared with the TBI arm (significant for naïve CD4
+
 cells and a trend for the 
CD4 memory/effector population [Figure 2]). There were no significant differences between arms 
in absolute counts of naïve and memory/effector CD8
+
 T cells, naïve and memory B cells, 
monocytes, and myeloid and plasmacytoid dendritic cells at any posttransplantation time point and 
in the counts of NK cells and naïve and memory/effector CD4 T cells on day 180 and 365 (data not 
shown). 
 
Figure 2.  
Immune reconstitution. Mean absolute numbers of natural killer (NK) cells (A), CD4
+
 (B), naïve 
CD4
+
 (C), and memory/effector CD4
+
 (D) cells at days 28 (TBI: n = 16; FLU/TBI: n = 7) and 90 
(TBI: n = 8; FLU/TBI: n = 13) after transplantation in patients conditioned with 2-Gy total body 
irradiation only (TBI) or in combination with 90 mg/m
2
 fludarabine (FLU/TBI). Bars represent 





The cumulative incidences of grades II to IV and grades III to IV acute GVHD at 120 days in the 
TBI arm were 32% and 11%, respectively, and in the FLU/TBI arm, 46% (grades I to IV acute 
GVHD: HR, 1.60 [95% confidence interval (CI), .8 to 3.1]; P = .16) and 7% (grades III to IV acute 
GVHD: HR, .66 [95% CI, .2 to 2.7]; P = .56), respectively ( Figure 3A). Although the cumulative 
incidence of chronic GVHD was higher in the FLU/TBI arm at 3 years (72% versus 48%), the 
difference did not reach statistical significance (HR, 1.52 [.9 to 2.7]; P = .14) ( Figure 3B). 
 
Figure 3.  
Graft-versus-host disease. Cumulative incidences of grade II to IV acute (A) and chronic (B) 
GVHD among patients conditioned with 2-Gy total body irradiation only (TBI) or in combination 
with 90 mg/m
2
 fludarabine (FLU/TBI). 
 
Regimen-Related Toxicities, Infections, and NRM 
 
The most common toxicities were, as expected, reversible neutropenia and thrombocytopenia. In 
general, toxicities unrelated to the blood and bone marrow were mild with 14 patients in both arms 
(TBI arm: 32%, FLU/TBI arm: 34%) experiencing 1 or more grade III to IV toxicities. No 
differences in distribution of toxicities were observed between arms (Supplementary Table 1). One 
patient in the FLU/TBI arm developed a squamous cell carcinoma 3.5 years after transplantation. 
The cumulative 3-year incidences of bacterial (TBI: 64%, FLU/TBI: 68%; P = .52), viral (TBI: 
60%, FLU/TBI: 68%; P = .27), and fungal (TBI: 21%, FLU/TBI 22%; P = .87) infections were 
similar in the 2 arms. NRM at 3 years was 9% in the TBI arm and 7% in the FLU/TBI arm (HR, .67 
[95% CI, .1 to 3.0]; P = .59) ( Figure 4). Of the 4 NRM deaths in the TBI arm, 1 was due to chronic 
GVHD, and 1 was due to multiple pulmonary emboli and hemolytic uremic syndrome, whereas 2 
were caused by GVHD complicated with severe sepsis on days 194 and 287 after transplantation. In 
the FLU/TBI arm, 3 NRM deaths were observed on days 9, 59, and 254, all associated with sepsis. 
 
Figure 4.  
Nonrelapse mortality. Cumulative incidence of nonrelapse mortality among patients 





Relapse and Survival 
 
At the time of analysis, the median follow-up of 48 surviving patients was 5 (range, 1.5 to 8) years. 
There was a trend for a higher progression/relapse rate in the TBI arm than in the FLU/TBI arm 
(55% versus 40% at 3 years; HR, .55 [95% CI, .3 to 1.0]; P = .06) ( Figure 5A), which translated 
into a trend toward a higher relapse-related mortality (37% versus 28% at 3 years; HR, .53 [95% CI, 
.3 to 1.1]; P = .09) ( Figure 5B) and worse progression-free survival (36% versus 53% at 3 years; 
HR, .56 [95% CI, .3 to 1.0]; P = .05) ( Figure 6A). Because of limited sample size, it was not 
possible to evaluate if the effects of FLU vary according to disease; however, similar trends of 
increased relapse in the TBI arm were observed when patients with lymphoid and myeloid 
malignancies were analyzed separately (data not shown). 
 
 
Figure 5.  
Relapse or progression incidence and relapse-related mortality. Cumulative incidences of 
relapse or progression (A) and relapse-related mortality (B) among patients conditioned with 






Figure 6.  
Progression-free survival and overall survival. Cumulative incidences of progression-free 
survival (A) and overall survival (B) among patients conditioned with 2-Gy total body 
irradiation only (TBI) or in combination with 90 mg/m
2
 fludarabine (FLU/TBI). 
 
Twenty-six patients relapsed in the TBI arm. At the end of follow-up, 3 were alive with relapsed 
disease (HL, n = 2; NHL, n = 1), whereas 4 (HL, n = 1; NHL, n = 2; MM, n = 1) were brought back 
into remission. In the FLU/TBI arm, 16 patients relapsed, of whom 5 were alive at the end of 
follow-up. One of the 5 who had HL was brought back into remission, 3 had progressive disease, 
and 1 patient with CLL had stable disease. 
Compared with the TBI arm, there was a trend toward higher overall survival in the FLU/TBI arm 




Historically, the addition of FLU to 2-Gy TBI to the conditioning regimen successfully reduced the 
rejection rate from 20% to 3%, by augmenting the pretransplantation immunosuppression 4, 
5 and 17. In a retrospective analysis of the first 176 patients, however, the question of whether 
adding FLU to 2-Gy TBI-exposed patients at low to moderate risk of rejection to unnecessary 
toxicity was raised [5]. In the current study, 85 patients at low to moderate risk of rejection were 
randomized to conditioning with either 2-Gy TBI alone or in combination with FLU. Baseline 
characteristics were balanced between groups, except for a slight imbalance toward more patients 
with NHL compared with AML in the FLU/TBI group. Although the number of prior treatment 
regimens and transplantations were similar in both groups, 21 of 41 patients in the FLU/TBI arm 
had failed autologous transplantations. In the TBI group, 23 of 44 patients failed autografts and 3 
failed allografts. Only 2 rejections were observed in the trial, both in the TBI-only group. One had a 
prior allograft from a different donor, possibly indicating that donor cells given in the first 
transplantation were not adequately myelosuppressed with TBI only. For this reason, the current 
practice is to condition patients who have failed prior allografts with 3-Gy TBI in addition to FLU. 
The second patient who rejected the graft had only received 1 cycle of chemotherapy before 
transplantation, which possibly was insufficiently myelosuppressive. 
All patients had initial engraftment, even the 2 who experienced rejection. Donor granulocyte 
chimerism was prompt, with no difference between arms. However, significant differences were 
observed in the rate of achieving donor T and NK cell chimerism. Patients conditioned with 
FLU/TBI had significantly higher levels of donor T cell chimerism at days 28 and 84 after 
transplantation. Day-28 NK cell chimerism was also higher in the FLU/TBI group. Low levels of 
donor T and NK cell chimerism have previously been associated with graft rejection in settings of 
nonmyeloablative, reduced-intensity and in high-dose conditioning. In a cohort of 38 patients who 
underwent transplantation after conditioning with FLU/TBI, Keil et al. [18] observed that donor 
T cell chimerism <90% at day 28 was associated with a higher rejection rate. Similarly, analyses by 
Baron et al. have demonstrated that day-14 donor T and NK cell chimerism levels <50%, 
conditioning with 2-Gy TBI with or without FLU (90 mg/m
2
) were associated with increased graft 
rejection 19 and 20. In a recent study of pediatric patients conditioned with a variety of high-dose 
and reduced-intensity regimens, early low donor T and NK cell chimerism levels were also 
associated with increased risk of graft rejection, regardless of conditioning intensity [21]. 
Although the addition of FLU was associated with an increased number of days with absolute 
granulocyte counts below 500 cells/μL and a trend toward increased red blood cell transfusion 
needs, no increases in NRM or bacterial, viral, or fungal infection rates were observed. However, it 
is possible that the 2 early septic deaths in the FLU/TBI arm could be related to FLU. NRM rates in 
both arms were lower than in the previous retrospective analysis [5] that prompted the current 
study, probably reflecting the recent years' overall improvement in supportive care, which has 
lowered NRM in general and, in particular, also negated the effect of FLU on NRM. Although 55% 
of the patients in the current study had failed a high-dose transplantation before entering the trial, 
NRM rates still compared favorably to previously published data on nonmyeloablative regimens, 
such as fludarabine/busulfan in AML/MDS (NRM 26% at 2 years) [22] and 
fludarabine/cyclophosphamide/rituximab in follicular lymphoma (NRM 15% at 5 years) [23]. A 
recent registry study investigating the outcome of low-intensity conditioning allogeneic 
transplantation in patients with NHL who had relapsed after autologous transplantations, reported 
an NRM of 44% at 3 years [24]. 
In this study, the relapse/progression incidence, relapse-related mortality, and progression-free 
survival were superior in the FLU/TBI arm, whereas only nonsignificant trends toward higher rates 
of acute and chronic GVHD were observed. It is possible that some of the effect on relapse may be 
due to the antineoplastic effects of the FLU, although this is unlikely in this patient population. 
The observed differences in outcome between arms in our study were likely due to differences in 
donor T and NK cell chimerism kinetics. Our results are in agreement with previous observations 
by both Keil et al. [18] and our own group [19], where donor T cell chimerism <90% (day 28 after 
transplantation) and <75% (day 84 after transplantation) were associated with a higher risk of 
relapse and lower progression-free survival. Although it is agreed that the graft-versus-tumor effects 
and GVHD after HLA-identical HCT are mainly a product of T cell activity [25], the roles of NK 
cells are far less explored. Killer cell immunoglobulin-like receptor genes are inherited 
independently from HLA, and will be mismatched in 75% of matched related transplantations [26]. 
In 2 studies by Baron et al., in which patients were conditioned with FLU/TBI, and NK cell 
chimerism was investigated along with T cell chimerism, T cell chimerism was mainly associated 
with the development GVHD, whereas rapid development of NK cell chimerism was associated 
with lower relapse rates and better progression-free survival 20 and 27. Notably, no association 
between NK cell chimerism and GVHD was observed [27]. As T and NK cell chimerism correlated 
closely at day +28 in our study, it is an open question whether the superior outcomes in the 
FLU/TBI arm were due to faster, more complete donor T cell chimerism, NK cell chimerism, or 
both. 
Reconstitution of immune cells was similar between arms, except for NK and CD4
+
 T cells. Why 
only CD4
+
 T cell counts were affected in the current study is not clear, but these results are in line 
with findings by De Bock et al. that showed levels of CD4
+
 cells, including naïve CD4
+
, 
regenerated slower than other cell subsets after nonmyeloablative conditioning with fludarabine and 
low-dose TBI [28]. Although our findings should be interpreted with caution because of small 





 cells have been shown to be highly sensitive to depletion by fludarabine in CLL [29], 
whereas NK cells have been shown to be more resistant [30], explaining the higher NK and lower 
CD4
+
 cell counts in the FLU/TBI arm. Conversely, with 2-Gy TBI alone conditioning killing fewer 
T (including CD4
+
) cells, the higher levels of CD4
+
 cells could be a consequence of a longer period 
with mixed chimerism. 
In conclusion, the current study showed that in the setting of a randomized phase III clinical trial, 
the addition of FLU (30 mg/m
2
) for 3 days to conditioning with 2-Gy TBI before allogeneic HCT 
from HLA-matched related donors with CSP and mycophenolate mofetil as postgrafting GVHD 
prophylaxis is safe and efficacious. FLU did not increase NRM or the incidence of infections and 
was associated with lower relapse and better progression-free survival, probably because of the 
induction of higher levels of donor T and NK cell chimerism early after transplantation. 
Furthermore, the study suggests that donor engraftment in heavily pretreated patients is possible 
with only 2-Gy TBI, but that a lower conditioning intensity correlates to a slower speed of 
engraftment, which may be associated with a decrease in successful outcome. 
Although NRM is low with the current nonmyeloablative regimens, relapse still represents a 
challenge. In the context of reduced-intensity regimens, where conditioning intensity and 
antineoplastic activity is increased compared with the nonmyeloablative regimens, the possible 
beneficial effects on relapse rates are counterbalanced by an increase in NRM at 19% to 25% 31, 
32 and 33. 
A possible solution to this problem could be further studies with minimal conditioning intensity, 
where the issue of slow development of donor chimerism could be approached by augmenting the 
antitumor effect by adding disease-specific agents, such as anti-CD20 antibodies [34] or receptor 
tyrosine kinase inhibitors [35], in the posttransplantation period, thereby allowing full-donor 
chimerism ample time to develop. A different approach could also include substituting external 
beam radiation with targeted α-emitter – labeled anti-CD45 – based radioimmunotherapy, which 
reduces off-target radiation toxicity and increases radiation dose selectively in cells responsible for 
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